Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
Conclusions RBs in this patient population were generally safe. Pneumothorax was the most frequent complication; bleeding, while infrequent, increased the risk of severe events. The diagnostic yields and complications of any particular modality should therefore be discussed with prospective clinical trial participants.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Clinical Trials | CT Scan | Endotracheal Intubation | General Medicine | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Pneumothorax | Tarceva | Urology & Nephrology